About this source
- Kind
- Research
- Design
- RCT, Human clinical trial
- Population
- Human, severe dry eye including graft-versus-host disease, 9 patients (RGN-259 group 12 eyes, vehicle group 6 eyes), 2 US sites
- Sample size
- 9
- Primary or secondary
- primary
- Peer review
- peer reviewed
- Retraction status
- None known
- Date checked
- 14 November 2026
Limitations
Nine patients. The abstract gives no adverse-event counts and states only that the drops were safe and well tolerated. Verified from the Europe PMC abstract record.
Cited in
Severe dry eye Phase II, 9 patients
Thymosin beta-4 · Research finding
Preliminary
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.